OVERVIEW:
Skysis was founded to navigate the shifting commercial realities of the biopharmaceutical industry. As the healthcare landscape evolves, companies require real-time access to specialized expertise to drive operational performance and commercial success. Skysis partners with emerging, midsize, and large-scale biopharma organizations, delivering high-level strategic and tactical services designed to meet rigorous business objectives in a complex market.
ROLES:
Creative Direction
Graphic & Visual Design
Brand Design
Interactive Design
INSIGHT:
As Skysis expanded, its visual identity needed to reflect a more consolidated and mature service offering. The insight was that a premium consultancy’s brand must act as a visual shorthand for "trust" and "efficiency."
To move from a specialized boutique to a comprehensive partner, Skysis required a foundational design system that could simplify their diverse capabilities into a clear, cohesive narrative—proving they were as agile as the "new commercial realities" they helped their clients navigate..
OBJECTIVE:
The objective was to lead a total brand evolution, refreshing and developing new assets to provide a unified foundation for all future marketing. My role was to build this ecosystem from the ground up: I designed the primary brand identity, established a sophisticated color palette, and curated a professional typography set.
To further the brand’s reach, I developed a custom iconography library and a "branded" photography style. These ingredients were then fused into a comprehensive suite of print, digital, interactive, social, and environmental materials to ensure a seamless launch.
RESULTS:
The brand evolution successfully transformed the brand from a service provider into a modern industry authority. By consolidating their visual assets into a singular, high-performance library, Skysis gained the ability to communicate their value proposition with speed and precision across all channels.
The new identity provided the foundational stability necessary for long-term growth, allowing the firm to present a polished, unified front to stakeholders and prospective biopharma partners globally.
